Research and Clinical Trials on Fluvoxamine (Luvox, Faverin)
This list of current clinical research trials on Fluvoxamine (Luvox, Faverin) is followed by a short set of abstracts from the most recent research articles published on the drug.
Fluvoxamine (Luvox, Faverin) Clinical Research Trials
From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Fluvoxamine (Luvox, Faverin).
- Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
Status: Terminated, Condition Summary: Obsessive Compulsive Disorder - Lexapro and Pramipexole and to Treat Major Depression
Status: Recruiting, Condition Summary: Major Depression - Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
Status: Not yet recruiting, Condition Summary: Healthy Volunteer - Fluvoxamine Maleate in the Treatment of Depression/Depressive State: A Post-Marketing Clinical Study in Children and Adolescents
Status: Completed, Condition Summary: Major Depressive Disorder - Treatment of Youth With ADHD and Anxiety
Status: Completed, Condition Summary: Attention Deficit Hyperactivity Disorder; Anxiety, Separation; Social Phobia; Generalized Anxiety Disorder - Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Status: Completed, Condition Summary: SSRI-Refractory Obsessive-Compulsive Disorder - Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
Status: Active, not recruiting, Condition Summary: Schizophrenia - Treatment of Obsessive Compulsive Disorder in Children
Status: Recruiting, Condition Summary: Obsessive-Compulsive Disorder - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)
Status: Not yet recruiting, Condition Summary: Obsessive Compulsive Disorder - Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism
Status: Recruiting, Condition Summary: Major Depression - Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression
Status: Completed, Condition Summary: Major Depressive Disorder - Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?
Status: Completed, Condition Summary: Autism - Platelet Function in Patients Treated With SSRI and Non-SSRI Antidepressants
Status: Completed, Condition Summary: Depression - AV650 Drug-Drug Interaction Study
Status: Completed, Condition Summary: Healthy - Treatment for Anxiety in Children
Status: Completed, Condition Summary: Obsessive-Compulsive Disorder; Anxiety Disorders; Generalized Anxiety Disorder; Social Phobia; Separation Anxiety
Get These Clinical Trials as a Newsfeed
Current Research Literature on Fluvoxamine (Luvox, Faverin)
Here are abstracts for some of the latest research articles to have appeared on Fluvoxamine (Luvox, Faverin):
Br J Clin Pharmacol. 2009 Oct; 68(4): 574-9
Chetty M, d'Esposito F, Zhang WV, Glen J, Dore G, Stankovic Z, Edwards RJ, Ramzan I, Murray M
AIMS: To study the impact of risperidone (RISP) on clozapine (CLZ) biotransformation in vitro in microsomal fractions containing varying expression of CYP oxidases and in vivo in patients. METHODS: Human liver microsomes (n= 11) were assessed for expression of CYPs 1A2, 2D6 and 3A4, because these enzymes mediate RISP and CLZ oxidation. Inhibition of CLZ oxidation by RISP was assessed. Plasma CLZ elimination was estimated in patients with schizophrenia who received either CLZ alone or the CLZ-RISP combination (n= 10 per group). RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. (ii) RISP did not inhibit CLZ oxidation, regardless of variations in CYP expression. (iii) RISP co-administration did not impair CLZ clearance. CONCLUSIONS: No evidence was found for CYP-mediated inhibitory or pharmacokinetic interactions between RISP and CLZ. Occasional literature reports of such interactions may involve other pathways that participate in CLZ disposition.
Serotonin reuptake inhibitor and fluvoxamine-induced severe hyponatremia in a 49-year-old man.
Case Report Med. 2009; 2009: 585193
Gabriel A
Objectives. To describe a case of fluvoxamine-induced severe hyponatremia, most likely due to abnormal antidiuretic hormone excretion (SIADH), and to discuss the implication for maintenance treatments for these patients. Clinical Observations. Although this syndrome had its incidence most commonly among the elderly, we report a case of severe hyponatremia (serum sodium
Photosensitivity associated with selective serotonin reuptake inhibitors.
Clin Exp Dermatol. 2009 Oct 10;
Doffoel-Hantz V, Boulitrop-Morvan C, Sparsa A, Bonnetblanc JM, Dalac S, Bédane C
Summary Selective serotonin reuptake inhibitors (SSRIs) are a widely prescribed group of antidepressants. We report three cases of photosensitivity induced by fluvoxamine and paroxetine. These photoallergic reactions suggest cross-reactivity between different molecules. Methylation metabolism could explain common photosensitization. Although these drugs are widely prescribed, such photosensitization is rare. Nevertheless, we consider that clinicians and patients should be aware of the risk of photosensitization and these drugs should be stopped before phototherapy or prolonged sun exposure.
Trichotilliomania responding to low-dose fluvoxamine.
Psychiatry Clin Neurosci. 2009 Oct; 63(5): 701-2
Ikenouchi-Sugita A, Yoshimura R, Ueda N, Nakamura J
Neuromolecular Med. 2009 Sep 4;
Okuda A, Kishi T, Okochi T, Ikeda M, Kitajima T, Tsunoka T, Okumukura T, Fukuo Y, Kinoshita Y, Kawashima K, Yamanouchi Y, Inada T, Ozaki N, Iwata N
Several investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD). TSNAX is located immediately upstream of DISC1, and has been shown to undergo intergenic splicing with DISC1. It thus may also be influenced by translocation. To our knowledge, there are no reported gene-based association analyses between TSNAX and mood disorders in the Japanese population. We conducted a case-control study of Japanese samples (158 bipolar patients, 314 major depressive disorder patients, and 811 controls) with three tagging SNPs in TSNAX, selected using HapMap database. In addition, we performed an association analysis between TSNAX and the efficacy of fluvoxamine treatment in 120 Japanese patients with MDD. The MDD patients in this study had scores of 12 or higher on the 17 items of the Structured Interview Guide for Hamilton Rating Scale for Depression (SIGH-D). We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks, and clinical remission as an SIGH-D score of less than 7 at 8 weeks. We found an association between rs766288 in TSNAX and female MDD in the allele/genotype analysis. However, we did not find any association between TSNAX and BP or the fluvoxamine therapeutic response in MDD in the allele/genotype analysis or haplotype analysis. Our results suggest that rs766288 in TSNAX may play a role in the pathophysiology of female MDD in the Japanese population. A replication study using larger samples may be required for conclusive results, since our sample size was small.
Related Articles at CounsellingResource.com
From the Drugs and Mental Health section of our main blog:
- Are We Over-Medicating Ourselves?
- Weight Loss Drug Acomplia Yanked from Market Over Psychiatric Risks
- Placebo Pills for Children
- Long Live the Placebo!
- Easier Access to Clinical Trials and Research Abstracts
From the Medications section of ‘Ask the Psychologist’:
This page was last reviewed by Dr Greg Mulhauser, Monday, 1 June 2009.
The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/fluvoxamine-research.html
